About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Drug Everolimus Does Not Improve Overall Survival in Advanced Liver Cancer Patients

by Bidita Debnath on July 2, 2014 at 8:59 PM
 Drug Everolimus Does Not Improve Overall Survival in Advanced Liver Cancer Patients

A study in the July 2 issue of JAMA reveals that despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo.

Patients with advanced hepatocellular carcinoma (HCC; a type of liver cancer) have a median overall survival of less than l year, largely because of the absence of effective therapies. The drug sorafenib is the only systemic therapy shown to significantly improve overall survival in advanced HCC; however its benefits are mostly transient and modest, and disease eventually progresses. In preclinical models, everolimus prevented tumor progression and improved survival, according to background information in the article.

Advertisement

Andrew X. Zhu, M.D., Ph.D., of the Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, and colleagues randomly assigned 546 adults with advanced HCC whose disease progressed during or after sorafenib or who were intolerant of sorafenib to receive everolimus (n = 362) or placebo (n = 184), both given in combination with best supportive care and continued until disease progression or intolerable toxicity. In this phase 3 study, patients were enrolled from 17 countries between May 2010 and March 2012.

The researchers found no significant difference in overall survival between the two groups: there were 303 deaths (83.7 percent) in the everolimus group and 151 deaths (82.1 percent) in the placebo group. Median overall survival was 7.6 months with everolimus, 7.3 months with placebo. The disease control rate (the percentage of patients with a best overall response of complete or partial response or stable disease) was 56.1 percent (everolimus) and 45.1 percent (placebo).
Advertisement

"The results from [this study, EVOLVE-1] extend the list of failed phase 3 studies in advanced HCC, highlighting the challenge of developing effective therapies for this cancer," the authors write.

The researchers note that EVOLVE-l and the other failed phase 3 studies have provided several important lessons, including that it is difficult to assess efficacy signals from phase 2 trials; surrogate end points such as time to progression, progression-free survival, and response rate inconsistently predict overall survival in phase 3 trials; and clinical and biologic heterogeneity likely affects the performance of targeted therapies in HCC. "In the absence of well-characterized and validated predictive bio-markers, targeted agents will likely continue to have a high risk of failure if phase 3 trials are conducted in unselected populations."

Source: Newswise
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Research News

Disrupted Circadian Rhythm Elevates the Risk of Parkinson's Disease
Trouble with sleep and the body's clock may increase your risk for Parkinson's, as per a new study.
A Wake-Up Call for Women  Hot Flashes Could Point to Alzheimer's Risk
New study uncovers a link between nocturnal hot flashes and Alzheimer's risk in menopausal women, suggesting a potential biomarker.
Breakthrough Brain-Centered Approach Reduces Chronic Back Pain
Our discovery revealed that a minority of individuals attributed their chronic pain to their brain's involvement.
New Statement to Protect Athletes' Health Published
Relative Energy Deficiency in Sport syndrome is overlooked by athletes and can be worsened by 'sports culture' due to its perceived short-term performance benefits.
Brain Circuits That Shape Bedtime Rituals in Mice
New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Drug Everolimus Does Not Improve Overall Survival in Advanced Liver Cancer Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests